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CASE REPORT
INTRODUCTION
Proton pump inhibitor (PPI) is currently the most
effective acid suppression, replacing histamine-2
receptor antagonists (H2RA). At this time, this group of
drugs has become the standard treatment for
gastroesophageal reflux disease (GERD), Helicobacter
pylori eradication, peptic ulcer, and non-steroidal
anti-inflammatory drug (NSAID) gastropathy.1
Pantoprazole, the fourth generation benzimidazole, is
the newest PPI in the market right now. Pantoprazole has
a low potential to interact with the liver cytochrome P450
enzyme, and thus has minimal interaction with other drugs.
Several studies proved that this drug does not interact with
theophyllin, caffeine, digoxin, nifedipine, glibenclamide,
diclofenac, ethanol, warfarin, or carbamazepine. Thus, this
drug may be administered in cases of heart disorders
receiving anticoagulants and digoxin.2
Several studies have demonstrated that this drug is
quite effective for the treatment of peptic ulcer,
H. pylori eradication, GERD, functional dyspepsia,
upper gastrointestinal bleeding, and Zollinger-Ellison
syndrome.3
Up to now, there has been no report on the use of
pantoprazole in Indonesia. This paper reports two cases
of duodenal ulcer, where one case had a complication of
bleeding with a history of long-term use of NSAID. The
other case was that of duodenal ulcer in a patient with a
high dose of steroid. Endoscopic evaluation at 2 weeks,
after 5-day use of intravenous pantoprazole,
demonstrated significant improvements were found in
the two cases.
CASE REPORT
Case 1
A 72-year old male was admitted to the hospital with
a chief complaint of black stool since 2 days prior to
admission. The patient complained that since 2 days prior
to admission, he had tar black stools 3-4 times a day
with varying amounts, averaging 50 cc. The patient
denied any nausea or vomiting. He also denied prior
epigastric pain. The patient had suffered from
hypertension and regularly visited the doctor and took
captopril and 80 mg/day of aspilets since the previous
year. The patient denied taking drugs for rheumatism or
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traditional drugs. During physical examination, the
patient’s conjunctiva were not pale, his sclera not
jaundiced. Heart and lung examination results were
within normal limits. There was no abdominal
abnormality. Laboratory examination results were as
follows: hemoglobin 12.7 g/dl, Hematocryte 37, white
blood cell count 7600/uL, platelet count 153,000/uL,
albumin level 3.6 mg/dl, globulin level 1.5 mg/dl. The
patient underwent upper gastrointestinal tract endoscopy,
which demonstrated grade A esophagitis with hiatal
hernia, pangastritis and multiple ulcers in the duodenum.
The patient received 40 mg of intravenous pantoprazole
for 5 days, continued with oral pantoprazole for 7 days.
During hospitalization, there was no complaint of black
stool, and the patient was released on the 7th day in good
condition. Endoscopic evaluation on the 14th day of
pantoprazole treatment demonstrated an ulcer scar in
the duodenum and mild gastritis. There was no
abnormality in the esophagus.
pangastritis, and duodenal ulcer. Laboratory
examination results were as follows: hemoglobin level
14.1 g/dl, white blood cell count 18,300, platelet count
377,000, albumin level 4.3 mg/dl, globulin level 2.5 mg/dl,
ureum /creatinine level 35/1.1, and cito blood sugar 93
mg/dl.
DISCUSSION
Nonsteroidal antiinflammatory drugs (NSAIDs) are
commonly used in this part of the world. Its increased
use is followed by increased incidence of side effects of
gastric damage. A complication found after NSAID use
is upper gastrointestinal bleeding, which is usually
associated with gastric or duodenal ulcer.4
In this paper, we report two cases of NSAID use
and history of steroid use. These drugs resulted in the
gastrointestinal complication of duodenal ulcer.
Previous studies demonstrated the risk for the
development of ulcer when these two drugs are used,
particularly if used simultaneously. When corticosteroids
are used alone, peptic ulcer rarely develops. Thus, the
drug is not considered to be contraindicated.5 However,
high doses of corticosteroids increases the risk of peptic
ulcer and gastrointestinal bleeding.6
In the first case, we report an elderly male patient
with a history of long-term NSAID use who was
admitted with upper gastrointestinal bleeding. Elderly
patients are considered at high risk for the complication
of upper gastrointestinal bleeding with NSAID use. Other
risk factors for upper gastrointestinal tract bleeding are
history of gastrointestinal ulcer, high-dose NSAID use,
the simultaneous use of two kinds of NSAIDs, the use
of NSAIDs with anticoagulants, the use of NSAIDs with
corticosteroids, and long term use of NSAIDs. In
addition, smoking, drinking, and cardiovascular disease
are factors that initiate bleeding in NSAID-users.
In the case we report, there were several risk
factors for upper gastrointestinal bleeding, as follows:
age of over 60 years, long term use of NSAID, smoking,
and cardiovascular disease.
Actually, with the many factors existing in the
patient, various preventive measures have been
considered to avoid upper gastrointestinal tract
complications. Several preventive measures that can be
taken are as follows: choice of cyclooxygenase-2 (COX-
2)-selective NSAID; protective therapy with
prostaglandin analog, H-2 receptor antagonists, and
proton-pump inhibitors. In addition, other mucoprotective
drugs such as sucralphate and teprenone may be
administered.
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Figure 1. The Upper Gastrointestinal Tract Endoscopy
Showed Multiple Ulcer in Duodenum (A). Endoscopic
Evaluation on the 14th Day of Pantoprazole Treatment
Demonstrated an Ulcer Scar in The Duodenum (B)
Case 2
A 35-year old male was admitted to the hospital due
to a generalized itchy rash since 2 weeks prior to
admission. Two weeks prior to admission, the patient
had visited a physician for a cold and received 3 types of
drugs. After taking the drugs for a day, a generalized
itchy rash appeared. The patient also complained of
epigastric pain, nausea, occasional vomiting and
recurrent heartburn. Physical examination during
admission revealed generalized red papules. The patient
was diagnosed with maculopapular drug eruption and
received a high dose of prednisolone (40 mg/day) and
2x150 mg of ranitidine. After 5 days taking the drug, the
patient complained of epigastric pain, nausea, and
regurgitation. Endoscopy revealed grade A esophagitis,
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Unlike the first case, the second case was a young
patient who received a high dose of corticosteroids. The
patient actually had previously suffered from
uninvestigated dyspepsia. Thus, it is unclear whether the
patient had suffered from organic dyspepsia prior to the
administration of corticosteroids. In this case,
corticosteroid administration aggravated the dyspepsia.
Endoscopic evaluation revealed esophagitis, pangastritis,
and duodenal ulcer.
Cases of endoscopically-diagnosed NSAID
gastropathy should receive adequate treatment. In
principle, NSAID should be discontinued, and H2RA,
mucoprotectors, or proton-pump inhibitors should be
administered. Termination of drug use heals the mucous
lesion. It becomes a problem when the NSAID or
corticosteroid needs to be continued, as in the two cases
above.
Proton-pump inhibitors are currently considered as a
drug that could be administered along with NSAID. Thus,
patients requiring NSAIDs could still continue their
medication in spite of NSAID gastropathy. Current
scientific proof demonstrate that simultaneous use of
proton-pump inhibitors and NSAIDs reduces the risk of
peptic ulcer and its complications.7,8
In this case report, intravenous pantoprazole was able
to heal the gastroduodenal lesions that developed in the
NSAID gastropathy cases, where the drugs causing the
gastropathy, aspirin and prednisone, were still
administered simultaneously. Evaluation at two weeks
after intravenous pantoprazole administration
demonstrated healing of the duodenal ulcer.
In addition, the esophagitis detected during the first
endoscopy was no longer found at endoscopic
evaluation after 2 weeks of treatment. This demonstrates
that pantoprazole is not only effective to treat duodenal
ulcer, but also to simultaneously treat GERD. This
supports previous reports that pantoprazole is effective
for rapid treatment of esophagitis.9
CONCLUSION
We report two cases of duodenal ulcer and
esophagitis that occurred after long term use of NSAID
and high doses of corticosteroids. Intravenous
pantoprazole was administered for the two cases to treat
the gastroduodenal ulcer that occurred. After two weeks
of treatment with pantoprazole, significant lesion healing
was achieved in both cases.
This report demonstrates that the drug is quite
promising for the treatment of severe gastroduodenal
lesions. A case control study with a large sample is
required to further evaluate the efficacy of this drug.
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